272 related articles for article (PubMed ID: 23478499)
1. Predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2013 May; 23(3):245-51. PubMed ID: 23478499
[TBL] [Abstract][Full Text] [Related]
2. Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2014 May; 24(3):303-10. PubMed ID: 24625431
[TBL] [Abstract][Full Text] [Related]
3. Predicting high risk disease using serum and DNA biomarkers.
Vesprini D; Liu S; Nam R
Curr Opin Urol; 2013 May; 23(3):252-60. PubMed ID: 23449497
[TBL] [Abstract][Full Text] [Related]
4. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
5. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
Salagierski M; Schalken JA
J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
[TBL] [Abstract][Full Text] [Related]
6. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance.
Trock BJ
Curr Opin Urol; 2014 May; 24(3):293-302. PubMed ID: 24710054
[TBL] [Abstract][Full Text] [Related]
7. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
8. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
9. Contemporary grading for prostate cancer: implications for patient care.
Brimo F; Montironi R; Egevad L; Erbersdobler A; Lin DW; Nelson JB; Rubin MA; van der Kwast T; Amin M; Epstein JI
Eur Urol; 2013 May; 63(5):892-901. PubMed ID: 23092544
[TBL] [Abstract][Full Text] [Related]
10. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
12. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract][Full Text] [Related]
13. Cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
15. How accurately can MRI detect indolent disease?
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2014 May; 24(3):264-9. PubMed ID: 24625426
[TBL] [Abstract][Full Text] [Related]
16. The Prostate cancer Research International: Active Surveillance study.
Bangma CH; Bul M; Roobol M
Curr Opin Urol; 2012 May; 22(3):216-21. PubMed ID: 22453333
[TBL] [Abstract][Full Text] [Related]
17. From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer.
Schlomm T; Chun FKh; Erbersdobler A
Methods Mol Biol; 2010; 664():177-89. PubMed ID: 20690063
[TBL] [Abstract][Full Text] [Related]
18. The contemporary concept of significant versus insignificant prostate cancer.
Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
[TBL] [Abstract][Full Text] [Related]
19. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
[TBL] [Abstract][Full Text] [Related]
20. Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer.
Vis AN; van Rhijn BW; Noordzij MA; Schröder FH; van der Kwast TH
J Pathol; 2002 Jun; 197(2):148-54. PubMed ID: 12015737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
